Showing results (11-20 of 28) with videos related to
Sort By:
Pageof 3
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 23, 2011
Pegylated interferon α-2b plus ribavirin for Japanese chronic hepatitis C patients with normal alanine aminotransferaseMosaburo Kainuma, Norihiro Furusyo, Koichi Azuma, et al.World Journal of Gastroenterology|March 8, 2006
Interferon alpha plus ribavirin combination treatment of Japanese chronic hepatitis C patients with HCV genotype 2: a project of the Kyushu University Liver Disease Study GroupNorihiro Furusyo, Masaki Katoh, Yuichi Tanabe, et al.Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|March 28, 2012
An inadequate dose of ribavirin is related to virological relapse by chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirinEiichi Ogawa, Norihiro Furusyo, Eiji Kajiwara, et al.Journal of Hepatology|May 28, 2013
Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapyEiichi Ogawa, Norihiro Furusyo, Makoto Nakamuta, et al.Journal of Hepatology|April 2, 2013
Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis CNorihiro Furusyo, Eiichi Ogawa, Makoto Nakamuta, et al.Journal of Hepatology|October 27, 2012
Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter studyEiichi Ogawa, Norihiro Furusyo, Eiji Kajiwara, et al.Internal Medicine (Tokyo, Japan)|March 21, 2015
Bacterial infection as an adverse effect of telaprevir-based triple therapy for chronic hepatitis C infectionAkira Kawano, Eiichi Ogawa, Norihiro Furusyo, et al.Journal of Gastroenterology and Hepatology|February 6, 2008
Association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients: project of the Kyushu University Liver Disease Study GroupNorihiro Furusyo, Eiji Kajiwara, Kazuhiro Takahashi, et al.World Journal of Gastroenterology|September 17, 2010
Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis CMosaburo Kainuma, Norihiro Furusyo, Eiji Kajiwara, et al.Journal of Gastroenterology and Hepatology|November 22, 2011
Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease StudyEiichi Ogawa, Norihiro Furusyo, Eiji Kajiwara, et al.Pageof 3